0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > VEGF-C

VEGF-C

VEGF-C Molecule Information

Name:Vascular endothelial growth factor C
Target Synonym:VEGFC;Flt4-L;Flt4 ligand;VRP;Vascular endothelial growth factor C;Vascular endothelial growth factor-related protein;VEGF-C
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase ?

VEGF-C Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
VEC-H4225 Human Human VEGF-C / Flt4-L Protein, His Tag
VEC-H4225-structure
VEC-H4225-sds
VEC-H4225-elisa_1

VEGF-C Molecule Synonym Name

VEGFC,Flt4-L,VRP

VEGF-C Molecule Background

Vascular endothelial growth factor C is also known as VEGFC, Flt4-L and VRP, it contains the C-terminal propeptide which has an unusual structure with tandemly repeated cysteine-rich motifs. Upon biosynthesis, VEGFC is secreted as a non-covalent momodimer in an anti-parellel fashion. VEGFC is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family, is active in angiogenesis, lymphangiogenesis and endothelial cell growth and survival, and can also affect the permeability of blood vessels. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms that bind and activate VEGFR-3 receptors. Only the fully processed form can bind and activate VEGFR-2 receptors. The structure and function of this protein is similar to those of vascular endothelial growth factor D (VEGF-D). VEGFC may function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Overexpression of VEGF-C causes lymphatics to enlarge possibly facilitates metastasis.

VEGF-C References

VEGF-C Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
VEGF-C gene therapy (Herantis Pharma) Ad-VEGF-C; LX-1101,LX1101; LX 1101 Phase Ⅱ Herantis Pharma Secondary lymphedema Details
OPT-302 OPT-302; VGX-300,OPT302; VGX300,OPT 302; VGX 300 Phase Ⅱ Orphan Europe Age-related macular degeneration (AMD), Diabetic macular edema Details
VGX-100 VGX-100 Phase Ⅱ Vegenics, Ceres Oncology, Opthea Solid tumours, Eye disorders Details

This web search service is supported by Google Inc.

totop